Pfizer/PFE

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1YMAX

About Pfizer

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Ticker

PFE

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Albert Bourla

Employees

88,000

Headquarters

New york, United States

Pfizer Metrics

BasicAdvanced
$162B
Market cap
-
P/E ratio
-$0.06
EPS
0.68
Beta
$1.65
Dividend rate
5.86%
Dividend yield
$162B
0.67609
$40.37
$25.20
42M
$1.65
1.047
0.778
66.434
75.355
-0.12%
-0.30%
-0.15%
2.948
1.76
3.64%
5.76%
5.86%
-40.73%
-101.20%
11.99%
-31.78%
2.57%

What the Analysts think about Pfizer

Analyst Ratings

Majority rating from 26 analysts.
Hold

Pfizer Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
20.93% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15B
4.41%
Net income
$3.1B
-192.46%
Profit margin
20.93%
-188.54%

Pfizer Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.58%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.67
-$0.17
$0.10
$0.82
-
Expected
$0.57
-$0.34
-$0.22
$0.52
$0.45
Surprise
18.02%
-49.39%
-145.84%
56.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pfizer stock?

Pfizer (PFE) has a market cap of $162B as of June 17, 2024.

What is the P/E ratio for Pfizer stock?

The price to earnings (P/E) ratio for Pfizer (PFE) stock is 0 as of June 17, 2024.

Does Pfizer stock pay dividends?

Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of June 17, 2024, the dividend rate is $1.65 and the yield is 5.86%. Pfizer has a payout ratio of 0% on a trailing twelve-month basis.

When is the next Pfizer dividend payment date?

The next Pfizer (PFE) dividend payment date is unconfirmed.

What is the beta indicator for Pfizer?

Pfizer (PFE) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Pfizer stock price target?

The target price for Pfizer (PFE) stock is $32.55, which is NaN% below the current price of $. This is an average based on projections from 22 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pfizer stock

Buy or sell Pfizer stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing